Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of the Effect of 480 mg and 1200 mg of BI 201335 as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind, Four-way Crossover Phase-I-study With Moxifloxacin as Positive Control

NCT02182310 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02182310
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02182310 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of the Effect of 480 mg and 1200 mg of BI 201335 as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind, Four-way Crossover Phase-I-study With Moxifloxacin as Positive Control
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2008
Completion date
Not reported
Enrollment
56 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy